<DOC>
	<DOCNO>NCT00111787</DOCNO>
	<brief_summary>This Study design determine effective safe new investigational drug , lapatinib , combination paclitaxel treat patient newly diagnose inflammatory breast cancer . Tumor tissue collect pre-treatment , follow 14 day treatment time surgical resection examine pathologic response biologic activity IHC ( immunohistochemistry ) within tumor . Treatment consist 14 day lapatinib monotherapy follow 12 week combination therapy lapatinib paclitaxel . Blood sample hematology chemistry panel , MUGA/ECHO exams physical exam perform throughout study monitor safety .</brief_summary>
	<brief_title>Study Of Lapatinib In Combination With Paclitaxel In The Treatment Of Newly Diagnosed Inflammatory Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Inflammatory Breast Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Inclusion criterion : Tumor accessible multiple biopsy ECOG ( Eastern Cooperative Oncology Group ) performance status 02 Adequate bone marrow Renal hepatic function LVEF ( leave ventricular ejection fraction ) great 0 % base ECHO ( echocardiogram ) MUGA ( multigated acquisition ) . Exclusion criterion : Females pregnant nursing . Any unstable , preexist major medical condition . Received investigational drug within past 4 week . Had major surgery past 2 week . Currently receive amiodarone receive amiodarone past 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>breast cancer</keyword>
</DOC>